iCAD Overview

  • Year Founded
  • 1984

Year Founded

  • Status
  • Public

  • Employees
  • 66

Employees

  • Stock Symbol
  • ICAD

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $3.72
  • (As of Tuesday Closing)

iCAD General Information

Description

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Contact Information

Website
www.icadmed.com
Formerly Known As
Howtek
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 2 Townsend West
  • Suite 6
  • Nashua, NH 03063
  • United States
+1 (603)
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2 Townsend West
  • Suite 6
  • Nashua, NH 03063
  • United States
+1 (603)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iCAD Stock Performance

As of 08-Jul-2025, iCAD’s stock price is $3.72. Its current market cap is $101M with 27.3M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.72 $3.71 $1.19 - $4.01 $101M 27.3M 811K -$0.20

iCAD Financials Summary

As of 31-Mar-2025, iCAD has a trailing 12-month revenue of $19.5M.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 39,146 29,850 28,112 24,965
Revenue 19,528 19,608 17,318 19,802
EBITDA (5,211) (5,693) (7,294) (9,716)
Net Income (5,227) (5,616) (4,847) (13,656)
Total Assets 39,472 37,540 41,418 51,705
Total Debt 307 362 461 672
Public Fundamental Data provided by Morningstar, Inc. disclaimer

iCAD Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore iCAD‘s full profile, request access.

Request a free trial

iCAD Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one s
Diagnostic Equipment
Nashua, NH
66 As of 2024

Littleton, MA
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

iCAD Competitors (23)

One of iCAD’s 23 competitors is Mevion Medical Systems, a Private Equity-Backed company based in Littleton, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mevion Medical Systems Private Equity-Backed Littleton, MA
Synaptive Medical Venture Capital-Backed Toronto, Canada
ContextVision Corporation Stockholm, Sweden
Kheiron Medical Technologies Formerly VC-backed London, United Kingdom
Sun Nuclear Formerly PE-Backed Melbourne, FL
You’re viewing 5 of 23 competitors. Get the full list »

iCAD Patents

  • 185

    Total Documents Applications and Grants

  • Total Patents Families

  • 68

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

iCAD Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019384179-A1 System and method for assessing breast cancer risk using imagery Inactive 23-Nov-2018
AU-2025204096-A1 System and method for assessing breast cancer risk using imagery Pending 23-Nov-2018
EP-3884458-A1 System and method for assessing breast cancer risk using imagery Pending 23-Nov-2018
EP-3884458-A4 System and method for assessing breast cancer risk using imagery Pending 23-Nov-2018
US-11205265-B2 System and method for assessing breast cancer risk using imagery Active 23-Nov-2018 G06Q50/163
To view iCAD’s complete patent history, request access »

iCAD Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iCAD Acquisitions (8)

iCAD’s most recent deal was a Merger/Acquisition with VuCOMP for . The deal was made on 13-Jan-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
VuCOMP 13-Jan-2016 Merger/Acquisition Monitoring Equipment
VuCOMP (Breast Density software) 29-Apr-2015 Merger/Acquisition Decision/Risk Analysis
DermEbx 15-Jul-2014 Merger/Acquisition Therapeutic Devices
Radion 15-Jul-2014 Merger/Acquisition Enterprise Systems (Healthcare)
Xoft 30-Dec-2010 Merger/Acquisition Other Devices and Supplies
You’re viewing 5 of 8 acquisitions. Get the full list »

Ready to get started?

Request a free trial

iCAD ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

25.25 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,638

Rank

Percentile

Healthcare

Industry

of 636

Rank

Percentile

Health Care IT Services

Subindustry

of 32

Rank

Percentile

To view iCAD’s complete esg history, request access »

iCAD Exits (1)

iCAD’s most recent exit was on 30-Dec-2010 from Xoft. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Xoft 30-Dec-2010 Completed
To view iCAD’s complete exits history, request access »

iCAD Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Qualia Computing Beavercreek, OH 1997

iCAD FAQs

  • When was iCAD founded?

    iCAD was founded in 1984.

  • Where is iCAD headquartered?

    iCAD is headquartered in Nashua, NH.

  • What is the size of iCAD?

    iCAD has 66 total employees.

  • What industry is iCAD in?

    iCAD’s primary industry is Diagnostic Equipment.

  • Is iCAD a private or public company?

    iCAD is a Public company.

  • What is iCAD’s stock symbol?

    The ticker symbol for iCAD is ICAD.

  • What is the current stock price of iCAD?

    As of 08-Jul-2025 the stock price of iCAD is $3.72.

  • What is the current market cap of iCAD?

    The current market capitalization of iCAD is $101M.

  • What is iCAD’s current revenue?

    The trailing twelve month revenue for iCAD is $19.5M.

  • Who are iCAD’s competitors?

    Mevion Medical Systems, Synaptive Medical, ContextVision, Kheiron Medical Technologies, and Sun Nuclear are some of the 23 competitors of iCAD.

  • What is iCAD’s annual earnings per share (EPS)?

    iCAD’s EPS for 12 months was -$0.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »